

# RCTC - Réceptologie et ciblage thérapeutique en cancérologie

## Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. RCTC - Réceptologie et ciblage thérapeutique en cancérologie. 2015, Université Toulouse 3 - Paul Sabatier - UPS, Institut national de la santé et de la recherche médicale - INSERM. hceres-02034088

**HAL Id: hceres-02034088**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02034088>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# HCERES

High Council for the Evaluation of Research  
and Higher Education

Research units

HCERES report on research unit:

Réceptologie et Ciblage Thérapeutique en

Cancérologie

RCTC

Under the supervision of the following  
institutions and research bodies:

Université Toulouse 3 - Paul Sabatier - UPS

Institut National de la Santé Et de la Recherche

Médicale - INSERM

# HCERES

High Council for the Evaluation of Research  
and Higher Education

Research units

*In the name of HCERES,<sup>1</sup>*

Didier HOUSSIN, president

*In the name of the experts committee,<sup>2</sup>*

Gert STORM, chairman of the committee

---

Under the decree No.2014-1365 dated 14 november 2014,

<sup>1</sup> The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5)

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2)

## Evaluation report

This report is the result of the evaluation by the experts committee, the composition of which is specified below.

The assessments contained herein are the expression of an independent and collegial deliberation of the committee.

Unit name:	Réceptologie et ciblage thérapeutique en cancérologie UTLS3_08
Unit acronym:	RCTC
Label requested:	UMR Inserm Université
Present no.:	EA 4552
Name of Director (2014-2015):	Mr Daniel FOURMY
Name of Project Leader (2016-2020):	Mr Daniel FOURMY

## Expert committee members

Chair:	Mr Gert STORM, Utrecht University, The Netherlands
Experts:	Mr Jean-luc GALZI, CNRS University of Strasbourg, Illkirch Mr Michael PERRAIS, Lille (representative of the CSS Inserm)

### Scientific delegate representing the HCERES:

Ms Maryam MEHRPOUR

### Representatives of the unit's supervising institutions and bodies:

Ms Armelle BARELLI, délégation régionale de l'Inserm Midi-Pyrénées,  
Limousin  
Ms Christelle GUEGAN, délégation régionale de l'Inserm Midi-Pyrénées,  
Limousin  
Ms Anne ROCHAT, Inserm  
Mr Alexis VALENTIN, Université Toulouse 3  
Mr Philippe VALET (representative of the Doctoral School n° 151)

## 1 • Introduction

### History and geographical location of the unit

The research team is derived from a large team of a former inserm-associated unit that was evaluated in 2010. The research team in its present form has significantly reduced its manpower in order to make it fit with the scientific objectives. The laboratory now totally focusses on endocrine tumors that overexpress G protein-coupled receptors. The laboratory sits in an university building situated within the “Hôpital Rangueil”, in Toulouse.

### Management team

Head: Mr Daniel FOURMY

### HCERES nomenclature

SVE1 LS4; ST5; SVE1 LS7

### Unit workforce

Unit workforce	Number as at 30/06/2014	Number as at 01/01/2016
<b>N1:</b> Permanent professors and similar positions		
<b>N2:</b> Permanent researchers from Institutions and similar positions	2	2
<b>N3:</b> Other permanent staff (without research duties)	1	1
<b>N4:</b> Other professors (Emeritus Professor, on-contract Professor, etc.)		
<b>N5:</b> Other researchers from Institutions (Emeritus Research Director, Postdoctoral students, visitors, etc.)		
<b>N6:</b> Other contractual staff (without research duties)	1	1
<b>TOTAL N1 to N6</b>	<b>4</b>	<b>4</b>

Unit workforce	Number as at 30/06/2014	Number as at 01/01/2016
Doctoral students	3	
Theses defended	2	
Postdoctoral students having spent at least 12 months in the unit	2	
Number of Research Supervisor Qualifications (HDR) taken		
Qualified research supervisors (with an HDR) or similar positions	1	2

## 2 • Overall assessment of the unit

### Global assessment of the unit

The team is composed of a laboratory director who heads a team of 2 permanent position persons, one research-associate, and one engineer. One additional contract scientist belongs to the group and PhD as well as Master students are present.

The team has reduced its number of scientists in order to focus on a single research axis: endocrine tumors, in which the group studies the presence of overexpressed G protein-coupled receptors that can be used in targeted therapies towards cancer cells.

The laboratory has published a significant number of high impact publications in its field of expertise and has had the opportunity to write review articles, present the work in international meetings as well as in social and economical instances.

### Strengths and opportunities in relation to the context

Focusing of the research themes has allowed the group to gain impact in the community. The laboratory is now well recognized nationally and internationally for its skills and expertise.

### Weaknesses and threats related to the context

The team is under the responsibility of only one research institution, the University Toulouse 3 Paul Sabatier, whose means to support research are limited. This may hamper future project developments and research successes, especially in the field of targeting tumor cells with magnetic particles, a highly competitive topic.

### Recommendations

Partnership(s) with groups with pharmaceuticals/nanomedicine expertise to strengthen the translational program outlined in the application.

Merging with already established larger research centers/institutes to guarantee broad accessibility to required advanced equipment, to increase visibility and to support the preclinical translational research (in vivo evaluation).